Abstract Details

Title Real-world Treatment Patterns Among Patients With Chemotherapy-induced Peripheral Neuropathy in China: The Retrospective, Observational ReTARdant Study

Topic Pain

Presentation(s) P8 - Poster Session 8 (11:45 AM-12:45 PM)

Poster/Presentation
Number 14-008

Objective To investigate pharmacological treatment patterns in the real-world setting among patients with chemotherapy-induced peripheral neuropathy (CIPN) in China.

Background CIPN is one common adverse effect of neurotoxic chemotherapy, and current treatment patterns among Chinese patients with CIPN remain unclear.

Design/Methods This retrospective, observational study (NCT06546202) was based on electronic medical records from 5 hospitals in China. Patients who were diagnosed with CIPN and received index regimens between January 1, 2018, to December 31, 2021, were identified. Targeted regimens included tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, calcium channel ligands [CaLs], sodium channel blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], opioids, and neuropathic drugs [NeuDs]. Data were collected from the index date (the initiation date of the index regimens) to December 31, 2022. Patient characteristics and treatment patterns were summarized with descriptive statistics.

Results A total of 451 patients (mean age ± standard deviation, 56.6 ± 11.2 years; male, 56.5%; stage IV tumors, 40.4%; treatment naïve for CIPN, 45.7%) with CIPN were included. The common primary tumors were lung cancer (n=103, 22.8%), colorectal cancer (n=82, 18.2%), and breast cancer (n=74, 16.4%). At the index date, opioids (n=176, 39.0%), NSAIDs (n=163, 36.1%), NeuDs (n=154, 34.2%), and CaLs (n=108, 24.0%) were most frequently prescribed, with NeuDs (n=123, 27.3%) and NSAIDs+opioids (n=53, 11.8%) being the most common monotherapy and combination therapy, respectively. During observation period, treatment discontinuation, switch, and add-on of the index treatment were observed in 445 (98.7%), 106 (23.5%), and 53 (11.8%) patients, respectively. The discontinuation rates of the index treatment regimens were 83.5% at 30 days and 92.8% at 60 days.

Conclusions

In Chinese patients with CIPN, opioids, NSAIDs, NeuDs, and CaLs were the most commonly prescribed regimens. Treatment discontinuation was frequent. There is a need to improve treatment strategies for CIPN in clinical practice in China.

Authors/Disclosures
Yingchun Zhang PRESENTER	Dr. Zhang has received personal compensation for serving as an employee of Daiichi Sankyo (China) Holding Co., Ltd..
Xiaoyu Zhai	Mrs. Zhai has nothing to disclose.
Peng Mao, MD	Dr. Mao has nothing to disclose.
Yanxia Shi	Mrs. Shi has nothing to disclose.
Huihui Li, PhD	Dr. Li has received research support from National Natural Science Foundation of China.
Guohua Ren, PhD	Dr. Ren has nothing to disclose.
Tao Sun	Prof. Sun has nothing to disclose.
Duan Yangyang	Ms. Yangyang has nothing to disclose.
Na Guo, PhD	Dr. Guo has received personal compensation for serving as an employee of Daiichi Sankyo.
Min Li, Sr., NA	Ms. Li has received personal compensation for serving as an employee of Daiichi Sankyo (China) Holding Co., Ltd.
Bifa Fan (China-Japan Friendship Hospital)	Prof. Fan has nothing to disclose.
JUN ZHAO, MD	Dr. ZHAO has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for zai lab. Dr. ZHAO has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Beone.

��ɫ��

��ɫ��